Journal Mobile Options
Table of Contents
Vol. 63, No. 6, 2010
Issue release date: July 2010
Eur Neurol 2010;63:326–330

Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients

Zetterberg H. · Tullhög K. · Hansson O. · Minthon L. · Londos E. · Blennow K.
aInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, and bClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Aim: To examine the incidence of post-lumbar puncture headache (PLPH) in patients admitted for cognitive disturbances. Methods: The incidence of PLPH and other general (subdural hematoma, meningitis, encephalitis) or local (local pain, spinal hematoma, local infection) complications was evaluated in 1,089 consecutive patients (aged 23–89 years) who underwent lumbar puncture as a part of the routine diagnostic evaluation between February 2001 and March 2007 at a specialized memory clinic. Results: 28 (2.6%) of the patients reported PLPH of mild severity. No other local or general complications occurred. Conclusions: The incidence of PLPH in patients with cognitive disturbances is low and CSF analyses can thus be part of the diagnostic work-up at memory clinics.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Blennow K, de Leon MJ, Zetterberg H: Alzheimer’s disease. Lancet 2006;368:387–403.
  2. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ: Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008;28:4231–4237.
  3. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006;440:352–357.
  4. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27:2866–2875.
  5. Gotz J, Chen F, Van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in p301l τ transgenic mice induced by aβ 42 fibrils. Science 2001;293:1491–1495.
  6. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant τ and APP. Science 2001;293:1487–1491.
  7. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K: Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78:461–464.
  8. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E: Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 2007;24:118–124.
  9. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE: Reduced effectiveness of aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001;22:721–727.
  10. Garcia-Alloza M, Subramanian M, Thyssen D, Borrelli LA, Fauq A, Das P, Golde TE, Hyman BT, Bacskai BJ: Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the γ-secretase inhibitor LY-411575. Mol Neurodegener 2009;4:19.
  11. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE: Anti-aβ42- and anti-aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006;116:193–201.
  12. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.
  13. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative: cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 2009;65:403–413.
  14. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385–393.
  15. Gauthier S: Will CSF analysis become routine in people with memory complaints? Lancet Neurol 2009;8:595–596.
  16. Vilming ST, Kloster R: Post-lumbar puncture headache: clinical features and suggestions for diagnostic criteria. Cephalalgia 1997;17:778–784.
  17. Evans RW, Armon C, Frohman EM, Goodin DS: Prevention of post-lumbar puncture headaches. Report of the Therapeutics and Technology Assessment Subcommitee of the American Academy of Neurology. Neurology 2000;55:909–914.
  18. Tourtellotte WW, Haerer AF, Heller GL, Soners JE: Post-Lumbar Puncture Headaches. Springfield, Thomas, 1964.
  19. Vandam LD, Dripps RD: Long-term follow-up of patients who received 10,098 spinal anesthetics. JAMA 1956;161:586–591.
  20. Blennow K, Wallin A, Häger O: Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 1993;88:221–223.
  21. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-τ and CSF-Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373–379.
  22. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D: Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005;19:220–225.
  23. The International Classification of Headache Disorders, ed 2. Cephalalgia 2004;24(suppl 1):9–160.

    External Resources

  24. Turnbull DK, Shepherd DB: Post-dural puncture headache: pathogenesis, prevention and treatment. Br J Anaesth 2003;91:718–729.
  25. Straus SE, Thorpe KE, Holroyd-Leduc J: How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis? JAMA 2006;296:2012–2022.
  26. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.
  27. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, on behalf of the PBT2-201-EURO Study Group: Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7:779–786.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50